Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 695500 versus rituximab reference products in moderately to severely active rheumatoid arthritis
NL-OMON41649Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of MabionCD20 and rituximab in rheumatoid arthritis (RA) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: AUC0-tz, AUC0-infinity predicted and 2 more. Started Aug 2013; status: active, not recruiting.
02
Drugs
MabionCD20rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON41649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41649.